Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma - Wikidata - awgldk - TriplyDB

Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma

Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma

http://www.wikidata.org/entity/Q33394023

about

Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas New molecular targets in mantle cell lymphoma Combating the epigenome: epigenetic drugs against non-Hodgkin's lymphoma Trials with 'epigenetic' drugs: an update Novel agents in mantle cell lymphoma Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents Novel Drugs in Follicular Lymphoma Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.Panobinostat in lymphoid and myeloid malignancies.A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma.A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy.Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches.EP300 single nucleotide polymorphism rs20551 correlates with prolonged overall survival in diffuse large B cell lymphoma patients treated with R-CHOP.Molecular targeted approaches in mantle cell lymphoma.Histone deacetylase inhibitors: emerging mechanisms of resistance.Programmed cell death 5 mediates HDAC3 decay to promote genotoxic stress response.Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects.Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8.Molecular pathogenesis of mantle cell lymphoma.A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517.Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas An immediate transcriptional signature associated with response to the histone deacetylase inhibitor Givinostat in T acute lymphoblastic leukemia xenografts.Marginal zone lymphoma: old, new, targeted, and epigenetic therapies.Management of indolent lymphoma: where are we now and where are we going.SIRT1 activation enhances HDAC inhibition-mediated upregulation of GADD45G by repressing the binding of NF-κB/STAT3 complex to its promoter in malignant lymphoid cells.Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies.The antiparasitic clioquinol induces apoptosis in leukemia and myeloma cells by inhibiting histone deacetylase activity.Loss of the proteins Bak and Bax prevents apoptosis mediated by histone deacetylase inhibitors.Role of Helicobacter pylori in gastric mucosa-associated lymphoid tissue lymphomas Gene mutations and actionable genetic lesions in mantle cell lymphoma.A histone deacetylase inhibitor improves hypothyroidism caused by a TRα1 mutant.Toxicological and metabolic considerations for histone deacetylase inhibitors.Targeting oncogenic and epigenetic survival pathways in lymphoma.Nodal marginal zone lymphoma.Targeted therapy of epigenomic regulatory mechanisms controlling the epithelial to mesenchymal transition during tumor progression.

P2860

Q26744080-8A1BD1DD-40A2-494E-AACB-2E0D1E0CAB76 Q26782506-D5EAEA85-4E7A-4F3A-AAAE-71E03F25B951 Q26821766-509CC5B7-7195-4853-B4E9-E5D8B9B9E328 Q26851166-F3797743-5994-4DC3-96FB-D7A725164DF5 Q27000542-8512EBD9-258D-46BF-B975-9FEBD7A74797 Q27011763-84C75871-4B04-42BF-ADA9-E2875C39DB29 Q28075606-79FB353A-5ED4-4401-A748-6677F4A25111 Q28076335-821D84ED-B61C-4307-9B26-4F29E6D26C5D Q28082536-BE5B3812-C8A5-498F-B72C-ED6DCB42F666 Q33405714-A3480204-8342-4701-94EB-5A515A912484 Q33408889-D6C24D5E-5A12-4351-A278-5C6A7A0C5788 Q33413857-430F1EAF-2DAB-4CC1-BA57-B1222D9AB7C7 Q33419840-E38376DC-0EDD-4A74-B89C-F4B5DFE4ABC3 Q33431680-E568862B-F2DE-4FBD-9FFB-9CF872B0924F Q33438732-1F162AD0-7FA9-4C55-9C20-AFFA08BADC62 Q33586239-D161B4EC-58DE-43DD-8240-0B035693E6A1 Q33909338-36477E4D-C410-4F5A-B0AD-785A80A63099 Q35127368-6D2A7130-EC0C-4D3A-BF21-05BB5AF30A0F Q35592607-9A5127EC-D72E-4080-8204-DBCBB676E968 Q35813589-41287EFB-90D7-4891-B51C-B618906D8C8A Q35939690-04B8DDF2-B7D9-481B-AC5B-320A2471D0AF Q36019774-D24012B1-4A9C-4608-8B7D-FB89DE072690 Q36290246-3D291B04-FC25-474F-AEF3-08CCCB10FFA4 Q36337623-E99A7B69-7875-4C1E-8A6D-D21BDF7F5028 Q36645808-40A9DB2E-3333-4CD7-A937-19633B243679 Q36703448-E0C2158B-075E-4262-B8EA-DF32DD9A5813 Q36751751-0035D039-9B34-4F0A-B650-E97CAF2A3281 Q36768594-08510EEE-292C-4491-BAD9-EB4D801F203A Q36784860-A4964B0E-9330-42B9-8E6A-F98A3222B863 Q36907129-433C050E-C894-43E3-AC80-236E99818960 Q37178611-623D4757-D610-4D27-8F93-FF76FD19D0EC Q37333839-011F06FB-24F4-4D78-9AD5-5D7F80792868 Q37505528-22492467-6031-4410-A4B1-4395019F2A31 Q37578581-B209E7BC-878F-45B1-8F05-8D408F95AAF0 Q37629080-2A7C5839-9D12-460A-BCE0-097318AEE0AA Q37708375-CC6DBEFC-480D-4762-8319-A8AA7DED6C26 Q38071321-70111B8E-2D7E-4916-B7AC-CDD7B367CC62 Q38084734-E2371C10-2880-4EA6-B33D-15D6FF3FA1BC Q38134139-7B9FBC16-E8B1-46A0-A4F5-A3CBAA0757E1 Q38212160-7AEBA47B-3C21-46D0-994B-DC0A1ADFA9DE

P2860

Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma

http://www.wikidata.org/entity/Q33394023

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Phase II study of vorinostat f ...... phoma and mantle cell lymphoma

@ast

Phase II study of vorinostat f ...... phoma and mantle cell lymphoma

@en

type

label

Phase II study of vorinostat f ...... phoma and mantle cell lymphoma

@ast

Phase II study of vorinostat f ...... phoma and mantle cell lymphoma

@en

prefLabel

Phase II study of vorinostat f ...... phoma and mantle cell lymphoma

@ast

Phase II study of vorinostat f ...... phoma and mantle cell lymphoma

@en

P1433

Q33394023-E3D21401-8B80-45D8-BF17-327EDB522FD9

P1476

Q33394023-2C0C46D0-F205-4FD6-9E8C-076635741ACB

P2093

Q33394023-243127DA-CC1B-484D-93AB-B7099799D54B

Q33394023-494B85FF-7D8F-4D4B-9DE0-AC39A30AD622

Q33394023-4D05EA62-BB8C-4E6B-988A-648DA14E6938

Q33394023-6052E7A2-AD69-4043-A3B2-813FDE998596

Q33394023-74FBDF75-6587-438A-8811-1D6431897CB0

Q33394023-8F53BD94-82AA-4E67-AFB5-1937E9A84989

Q33394023-A085B370-FEEF-4198-B503-D19C757A6575

Q33394023-B68A397C-92C0-4755-A68C-ECB2DD44D0F9

Q33394023-C06B4CC5-FD9A-4DD6-99D7-F0AEB24361A1

Q33394023-D6CA4C32-3A5F-4C16-9616-EBAE5E237D05

P2860

Q33394023-069351EA-C72E-42B2-A71E-BA2B833256A8

Q33394023-28415B74-FB96-4B9D-B28F-EA1830C83473

Q33394023-37514734-7DB7-4196-A9FD-922308BA51EE

Q33394023-472FECEB-2A2E-40AF-8FFF-A37982AA7651

Q33394023-4DE91212-4665-4181-96A9-E8C6EFDC7127

Q33394023-5E5B1B28-3D8C-4274-B62B-ACF276C821A5

Q33394023-62502FFE-BBAE-4960-BE0E-2FD7C127920D

Q33394023-7E9E4FF8-B580-4424-9C08-12E864B8FFC7

Q33394023-87BE75FC-072B-438D-A2EF-B684C91FF349

Q33394023-90320DD8-55F0-48C1-9CEB-39A8DC5FA0DA

P304

Q33394023-FABC490D-FB89-49A4-B6E8-80A3F78E81DE

P31

Q33394023-813A58B9-5A0B-4B27-AEBE-689573B39BFF

P356

Q33394023-0077062D-9966-40D0-8064-376A3EF11E7A

P407

Q33394023-EFFCB84C-C5AA-4259-A25C-A1FB2B61D54E

P433

Q33394023-D4D5717B-680D-4E88-BA8D-E0D3CD9AC4DA

P478

Q33394023-A646DF1B-B13D-431A-9378-9F02C60BFF87

P50

Q33394023-EF631079-2A18-49AC-A358-EC58EACCE389

P577

Q33394023-936FEE23-A313-463A-95F4-ABD1701CD149

P698

Q33394023-6DE8FB87-DB0A-404C-9E88-CF932F1B1B14

P932

Q33394023-BD995772-B756-4582-995A-0FC4C76B9624

P356

JCO.2010.32.1398

P1433

Journal of Clinical Oncology

P1476

Phase II study of vorinostat f ...... phoma and mantle cell lymphoma

@en

P2093

Arnold J Rotter

http://www.w3.org/2001/XMLSchema#string

Auayporn Nademanee

http://www.w3.org/2001/XMLSchema#string

Bernadette Pulone

http://www.w3.org/2001/XMLSchema#string

Deron Matsuoka

http://www.w3.org/2001/XMLSchema#string

Edward Newman

http://www.w3.org/2001/XMLSchema#string

Igor Espinoza-Delgado

http://www.w3.org/2001/XMLSchema#string

Jasmine Zain

http://www.w3.org/2001/XMLSchema#string

Leslie Popplewell

http://www.w3.org/2001/XMLSchema#string

Maria Delioukina

http://www.w3.org/2001/XMLSchema#string

Mark Kirschbaum

http://www.w3.org/2001/XMLSchema#string

P2860

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

Statistical methods in cancer research. Volume II--The design and analysis of cohort studies

Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.

Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.

Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.

Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.

Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma.

Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes.

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma.

P304

1198-1203

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2010.32.1398

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

David R Gandara

P577

2011-02-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21300924

http://www.w3.org/2001/XMLSchema#string

P932

3083875

http://www.w3.org/2001/XMLSchema#string